New pain block may cut morphine use after lung surgery
NCT ID NCT07367581
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests two different nerve blocks to control pain after lung cancer surgery. 70 adults will receive either a costotransverse foramen block or a thoracic paravertebral block, both using the numbing drug bupivacaine. The goal is to see which block reduces the need for morphine and improves pain relief.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- bupivacaine
- What this could lead to
- If one block works better, it could mean less pain and less morphine after lung surgery, helping patients recover faster.
- What could go wrong
- This is a small, early-stage trial with only 70 people. The results may not apply to everyone, and nerve blocks carry small risks like infection or bleeding.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 70 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2026
- Expected to finish
-
Jun 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age \> 18 years and ≤ 65 years old. * American Society of Anesthesiologists (ASA) physical status II-III. * Body mass index 18-35 kg/m2. * Patients scheduled for thoracotomies for lung cancer. Exclusion Criteria: * Patient refusal. * History of sensitivity to local anesthetics. * History of psychological disorders. * Contraindication to regional anesthesia, e.g., local sepsis, pre-existing peripheral neuropathies, and coagulopathy. * Severe respiratory, cardiac, hepatic, or renal disease. * Morbid obesity. * Uncooperative patients. * Patients on chronic pain therapy.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Costotransverse foramen block are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Cairo University
RECRUITINGCairo, 12613, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an Anti-Fibrotic drug shield lungs from radiation after immunotherapy?
- App aims to catch a hidden radiotherapy side effect
- Which nerve block wins for lung surgery pain?
- Amazon plant put to the test against Cancer's relentless tiredness
- Can a virtual stress program help working spouses care for cancer patients without burning out?
- Freezing probe aims to kill lung tumors through the airways